Structured Treatment of Gastroesophageal Reflux in a Company Health Care Setting, -Effect on Quality of Life, Symptoms and Productivity

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00884247
First received: April 17, 2009
Last updated: December 6, 2010
Last verified: December 2010

April 17, 2009
December 6, 2010
April 2009
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00884247 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Structured Treatment of Gastroesophageal Reflux in a Company Health Care Setting, -Effect on Quality of Life, Symptoms and Productivity
A Prospective, Non Interventional Study to Evaluate the Effects on Quality of Life, Symptoms and Productivity in Patients With Gastroesophageal Reflux Disease (GERD) After 6 Weeks Structured Treatment in a Company Health Care Setting

The study aims to evaluate if a GERD treatment programme, in accordance with current regional recommendations, in a company health care setting, has an impact on health related quality of life (HRQoL), symptoms, and productivity in GERD patients.

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Company health care setting

GERD
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
36
June 2009
Not Provided

Inclusion Criteria:

  • Female and/or male aged > 18 years
  • Diagnosis of GERD confirmed
  • Prescription of GERD treatment or already receiving GERD treatment

Exclusion Criteria:

  • Any symptom suggesting a need for further investigation
  • Previous participation in the present study
  • Current participation in a clinical study or participation in a clinical study during the last 30 days
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Sweden
 
NCT00884247
NIS-GSE-DUM-2009/1
No
Svante Sjöstedt/MC MDOTA, AstraZeneca
AstraZeneca
Not Provided
Study Director: Svante Sjöstedt, MD, PhD AstraZeneca Sweden
Principal Investigator: Dan Regberg, MD AstraZeneca Sweden
AstraZeneca
December 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP